Host	0	4	O
-	4	5	O
derived	5	12	O
angiopoietin	13	25	B-Gene_or_gene_product
-	25	26	I-Gene_or_gene_product
2	26	27	I-Gene_or_gene_product
affects	28	35	O
early	36	41	O
stages	42	48	O
of	49	51	O
tumor	52	57	B-Pathological_formation
development	58	69	O
and	70	73	O
vessel	74	80	B-Multi-tissue_structure
maturation	81	91	O
but	92	95	O
is	96	98	O
dispensable	99	110	O
for	111	114	O
later	115	120	O
stages	121	127	O
of	128	130	O
tumor	131	136	B-Pathological_formation
growth	137	143	O
.	143	144	O

The	146	149	O
angiopoietin	150	162	B-Gene_or_gene_product
/	162	163	O
Tie2	163	167	B-Gene_or_gene_product
system	168	174	O
has	175	178	O
been	179	183	O
identified	184	194	O
as	195	197	O
the	198	201	O
second	202	208	O
vascular	209	217	B-Multi-tissue_structure
-	217	218	O
specific	218	226	O
receptor	227	235	O
tyrosine	236	244	O
kinase	245	251	O
system	252	258	O
controlling	259	270	O
vessel	271	277	B-Multi-tissue_structure
assembly	278	286	O
,	286	287	O
maturation	288	298	O
,	298	299	O
and	300	303	O
quiescence	304	314	O
.	314	315	O

Angiopoietin	316	328	B-Gene_or_gene_product
-	328	329	I-Gene_or_gene_product
2	329	330	I-Gene_or_gene_product
(	331	332	O
Ang	332	335	B-Gene_or_gene_product
-	335	336	I-Gene_or_gene_product
2	336	337	I-Gene_or_gene_product
)	337	338	O
is	339	341	O
prominently	342	353	O
up	354	356	O
-	356	357	O
regulated	357	366	O
in	367	369	O
the	370	373	O
host	374	378	O
-	378	379	O
derived	379	386	O
vasculature	387	398	B-Multi-tissue_structure
of	399	401	O
most	402	406	O
tumors	407	413	B-Pathological_formation
,	413	414	O
making	415	421	O
it	422	424	O
an	425	427	O
attractive	428	438	O
candidate	439	448	O
for	449	452	O
antiangiogenic	453	467	O
intervention	468	480	O
.	480	481	O

Yet	482	485	O
,	485	486	O
the	487	490	O
net	491	494	O
outcome	495	502	O
of	503	505	O
Ang	506	509	B-Gene_or_gene_product
-	509	510	I-Gene_or_gene_product
2	510	511	I-Gene_or_gene_product
functions	512	521	O
on	522	524	O
tumor	525	530	B-Pathological_formation
angiogenesis	531	543	O
is	544	546	O
believed	547	555	O
to	556	558	O
be	559	561	O
contextual	562	572	O
depending	573	582	O
on	583	585	O
the	586	589	O
local	590	595	O
cytokine	596	604	O
milieu	605	611	O
.	611	612	O

Correspondingly	613	628	O
,	628	629	O
Ang	630	633	B-Gene_or_gene_product
-	633	634	I-Gene_or_gene_product
2	634	635	I-Gene_or_gene_product
manipulatory	636	648	O
therapies	649	658	O
have	659	663	O
been	664	668	O
shown	669	674	O
to	675	677	O
exert	678	683	O
protumorigenic	684	698	O
as	699	701	O
well	702	706	O
as	707	709	O
antitumorigenic	710	725	O
effects	726	733	O
.	733	734	O

To	735	737	O
clarify	738	745	O
the	746	749	O
role	750	754	O
of	755	757	O
Ang	758	761	B-Gene_or_gene_product
-	761	762	I-Gene_or_gene_product
2	762	763	I-Gene_or_gene_product
for	764	767	O
angiogenesis	768	780	O
and	781	784	O
tumor	785	790	B-Pathological_formation
growth	791	797	O
in	798	800	O
a	801	802	O
definite	803	811	O
genetic	812	819	O
experimental	820	832	O
setting	833	840	O
,	840	841	O
the	842	845	O
present	846	853	O
study	854	859	O
was	860	863	O
aimed	864	869	O
at	870	872	O
comparatively	873	886	O
studying	887	895	O
the	896	899	O
growth	900	906	O
of	907	909	O
different	910	919	O
tumors	920	926	B-Pathological_formation
in	927	929	O
wild	930	934	O
-	934	935	O
type	935	939	O
and	940	943	O
Ang	944	947	B-Gene_or_gene_product
-	947	948	I-Gene_or_gene_product
2	948	949	I-Gene_or_gene_product
-	949	950	O
deficient	950	959	O
mice	960	964	O
.	964	965	O

Lewis	966	971	B-Pathological_formation
lung	972	976	I-Pathological_formation
carcinomas	977	987	I-Pathological_formation
,	987	988	O
MT	989	991	B-Pathological_formation
-	991	992	I-Pathological_formation
ret	992	995	I-Pathological_formation
melanomas	996	1005	I-Pathological_formation
,	1005	1006	O
and	1007	1010	O
B16F10	1011	1017	B-Pathological_formation
melanomas	1018	1027	I-Pathological_formation
all	1028	1031	O
grew	1032	1036	O
slower	1037	1043	O
in	1044	1046	O
Ang	1047	1050	B-Gene_or_gene_product
-	1050	1051	I-Gene_or_gene_product
2	1051	1052	I-Gene_or_gene_product
-	1052	1053	O
deficient	1053	1062	O
mice	1063	1067	O
.	1067	1068	O

Yet	1069	1072	O
,	1072	1073	O
tumor	1074	1079	B-Pathological_formation
growth	1080	1086	O
in	1087	1089	O
wild	1090	1094	O
-	1094	1095	O
type	1095	1099	O
and	1100	1103	O
Ang	1104	1107	B-Gene_or_gene_product
-	1107	1108	I-Gene_or_gene_product
2	1108	1109	I-Gene_or_gene_product
-	1109	1110	O
deficient	1110	1119	O
mice	1120	1124	O
dissociated	1125	1136	O
during	1137	1143	O
early	1144	1149	O
stages	1150	1156	O
of	1157	1159	O
tumor	1160	1165	B-Pathological_formation
development	1166	1177	O
,	1177	1178	O
whereas	1179	1186	O
tumor	1187	1192	B-Pathological_formation
growth	1193	1199	O
rates	1200	1205	O
during	1206	1212	O
later	1213	1218	O
stages	1219	1225	O
of	1226	1228	O
primary	1229	1236	O
tumor	1237	1242	B-Pathological_formation
progression	1243	1254	O
were	1255	1259	O
similar	1260	1267	O
.	1267	1268	O

Analysis	1269	1277	O
of	1278	1280	O
the	1281	1284	O
intratumoral	1285	1297	B-Multi-tissue_structure
vascular	1298	1306	I-Multi-tissue_structure
architecture	1307	1319	I-Multi-tissue_structure
revealed	1320	1328	O
no	1329	1331	O
major	1332	1337	O
differences	1338	1349	O
in	1350	1352	O
microvessel	1353	1364	B-Tissue
density	1365	1372	O
and	1373	1376	O
perfusion	1377	1386	O
characteristics	1387	1402	O
.	1402	1403	O

However	1404	1411	O
,	1411	1412	O
diameters	1413	1422	O
of	1423	1425	O
intratumoral	1426	1438	B-Tissue
microvessels	1439	1451	I-Tissue
were	1452	1456	O
smaller	1457	1464	O
in	1465	1467	O
tumors	1468	1474	B-Pathological_formation
grown	1475	1480	O
in	1481	1483	O
Ang	1484	1487	B-Gene_or_gene_product
-	1487	1488	I-Gene_or_gene_product
2	1488	1489	I-Gene_or_gene_product
-	1489	1490	O
deficient	1490	1499	O
mice	1500	1504	O
,	1504	1505	O
and	1506	1509	O
the	1510	1513	O
vasculature	1514	1525	B-Multi-tissue_structure
had	1526	1529	O
an	1530	1532	O
altered	1533	1540	O
pattern	1541	1548	O
of	1549	1551	O
pericyte	1552	1560	B-Cell
recruitment	1561	1572	O
and	1573	1576	O
maturation	1577	1587	O
.	1587	1588	O

Ang	1589	1592	B-Gene_or_gene_product
-	1592	1593	I-Gene_or_gene_product
2	1593	1594	I-Gene_or_gene_product
-	1594	1595	O
deficient	1595	1604	O
tumor	1605	1610	O
vessels	1611	1618	O
had	1619	1622	O
higher	1623	1629	O
pericyte	1630	1638	B-Cell
coverage	1639	1647	O
indices	1648	1655	O
.	1655	1656	O

Recruited	1657	1666	O
pericytes	1667	1676	B-Cell
were	1677	1681	O
desmin	1682	1688	B-Gene_or_gene_product
and	1689	1692	O
NG2	1693	1696	B-Gene_or_gene_product
positive	1697	1705	O
and	1706	1709	O
predominately	1710	1723	O
alpha	1724	1729	B-Gene_or_gene_product
-	1729	1730	I-Gene_or_gene_product
smooth	1730	1736	I-Gene_or_gene_product
muscle	1737	1743	I-Gene_or_gene_product
actin	1744	1749	I-Gene_or_gene_product
negative	1750	1758	O
,	1758	1759	O
indicative	1760	1770	O
of	1771	1773	O
a	1774	1775	O
more	1776	1780	O
mature	1781	1787	O
pericyte	1788	1796	B-Cell
phenotype	1797	1806	O
.	1806	1807	O

Collectively	1808	1820	O
,	1820	1821	O
the	1822	1825	O
experiments	1826	1837	O
define	1838	1844	O
the	1845	1848	O
role	1849	1853	O
of	1854	1856	O
Ang	1857	1860	B-Gene_or_gene_product
-	1860	1861	I-Gene_or_gene_product
2	1861	1862	I-Gene_or_gene_product
during	1863	1869	O
tumor	1870	1875	B-Pathological_formation
angiogenesis	1876	1888	O
and	1889	1892	O
establish	1893	1902	O
a	1903	1904	O
better	1905	1911	O
rationale	1912	1921	O
for	1922	1925	O
combination	1926	1937	O
therapies	1938	1947	O
involving	1948	1957	O
Ang	1958	1961	B-Gene_or_gene_product
-	1961	1962	I-Gene_or_gene_product
2	1962	1963	I-Gene_or_gene_product
manipulatory	1964	1976	O
therapies	1977	1986	O
.	1986	1987	O

